PRESS RELEASE
Q3 2022 — Press release
Q3 2022PDF · 24 pages986 KB
FOR IMMEDIATE RELEASE Reported sales growth of 1.9% to $23.8 Billion with operational growth of 8.1%* and adjusted operational growth of 8.2%* Earnings per share (EPS) of $1.68 increasing 22.6% and adjusted EPS of $2.55 decreasing by 1.9%* Company is maintaining 2022 full-year guidance midpoints for adjusted operational sales and reported adjusted EPS; increasing adjusted operational EPS performance offsetting continued unfavorable currency impacts New Brunswick, N.J. (October 18, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for third- quarter 2022. “Our third quarter performance demonstrates our continued strength and resilience across all three of our businesses,” said Joaquin Duato, Chief Executive Officer. “Through the ongoing efforts of our teams around the world, we continue to navigate the dynamic macroeconomic environment and remain focused on delivering transformative healthcare solutions. Looking ahead, I remain confident in our business and ability to continue advancing our innovative portfolio and pipeline.” OVERALL FINANCIAL RESULTS Q3 ($ in Millions, except EPS) 2022 2021 % Change Reported Sales $23,791 $23,338 1.9% Net Earnings $4,458 $3,667 21.6% EPS (diluted) $1.68 $1.37 22.6% Q3 Non-GAAP* ($ in Millions, except EPS) 2022 2021 % Change Operational Sales1,2 8.1% Adjusted Operational Sales1,3 8.2% Adjusted Net Earnings1,4 $6,779 $6,968 (2.7%) Adjusted EPS (diluted)1,4 $2.55 $2.60 (1.9%) 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency -- 1 of 24 -- 4 Excludes intangible amortization expense and special items Note: values may have been rounded REGIONAL SALES RESULTS Q3 % Change ($ in Millions) 2022 2021 Reported Operational1,2 Currency Adjusted Operational1,3 U.S. $12,453 $11,963 4.1% 4.1% - 4.2% International $11,338 $11,375 (0.3%) 12.3% (12.6%) 12.4% Worldwide $23,791 $23,338 1.9% 8.1% (6.2%) 8.2% 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency Note: Values may have been rounded SEGMENT SALES RESULTS Q3 % Change ($ in Millions) 2022 2021 Reported Operational1,2 Currency Adjusted Operational1,3 Consumer Health4 $3,795 $3,812 (0.4%) 4.7% (5.1%) 4.8% Pharmaceutical4 $13,214 $12,882 2.6% 9.0% (6.4%) 9.2% MedTech $6,782 $6,644 2.1% 8.1% (6.0%) 8.1% Worldwide $23,791 $23,338 1.9% 8.1% (6.2%) 8.2% 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency 4 Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes Note: Values may have been rounded -- 2 of 24 -- THIRD QUARTER 2022 SEGMENT COMMENTARY: Adjusted operational sales* reflected below excludes the net impact of acquisitions and divestitures and translational currency. Consumer Health Consumer Health worldwide adjusted operational sales increased 4.8%*. Major contributors to growth include upper respiratory and analgesic products in the over-the-counter franchise, NEUTROGENA and AVEENO in Skin Health/Beauty and Women’s Health products outside the United States. Pharmaceutical Pharmaceutical worldwide adjusted operational sales grew 9.2%*, driven by DARZALEX (daratumumab), a biologic for the treatment of multiple myeloma, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis, STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, and INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults. Also contributing to growth were sales of the Janssen COVID-19 Vaccine (Ad26.COV2.S) for the prevention of the SARS-CoV-2 virus. This growth was partially offset by declines in sales of REMICADE (infliximab), a biologic approved for the treatment of several immune-mediated inflammatory diseases and IMBRUVICA (ibrutinib), an oral, once daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer. MedTech MedTech worldwide adjusted operational sales grew 8.1%*, driven primarily by electrophysiology products in Interventional Solutions, contact lenses in Vision, Trauma in Orthopaedics and wound closure products in General Surgery. NOTABLE NEW ANNOUNCEMENTS IN THE QUARTER: The information contained in this section should be read in conjunction with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investors section of the company’s -- 3 of 24 -- website at news releases, as well as www.factsabouttalc.com, www.factsaboutourprescriptionopioids.com, and www.LTLManagementInformation.com. Regulatory Decisions STELARA (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis Press Release European Commission Approves IMBRUVICA (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL) Press Release Janssen Marks First Approval Worldwide for TECVAYLI (teclistamab) with EC Authorisation of First-in-Class Bispecific Antibody for the Treatment of Patients with Multiple Myeloma Press Release U.S. FDA Approves IMBRUVICA (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease Press Release Data Release Janssen Announces New Data Supporting Safety and Efficacy of RYBREVANT and Lazertinib Combination for Patients with Non-Small Cell Lung Cancer and EGFR Mutations Press Release Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma Press Release TREMFYA (guselkumab) Demonstrates Higher Rates of Complete Skin Clearance with Earlier Treatment in Adults with Moderate to Severe Plaque Psoriasis in Phase 3b GUIDE Study Press Release Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 381 Press Release STELARA (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Through Four Years in Adults with Moderately to Severely Active Ulcerative Colitis1 Press Release Janssen Announces Late-Breaking Data from Two Gene Therapy Programs at the American Academy of Ophthalmology 2022 Annual Meeting Press Release Product Launches Biosense Webster Launches the OCTARAY Mapping Catheter with TRUEref Technology Press Release Johnson & Johnson Vision Introduces All Purpose EDOF, TECNIS Symfony OptiBlue IOL, the Latest PC-IOL Powered by InteliLight Technology Press Release Johnson & Johnson Vision Launches New Contact Lens Innovation to Help Meet the Needs of Digitally Intense Lifestyles: ACUVUE OASYS MAX 1-Day Press Release Biosense Webster Launches HELIOSTAR in Europe, the First Radiofrequency Balloon Ablation Catheter, Enabling Physicians to Perform More Efficient Cardiac Ablations1 Press Release Other Johnson & Johnson Announces $5 Billion Share Repurchase Program Press Release Johnson & Johnson Appoints Larry Merlo as Non-Executive Chair Designate of Planned New Consumer Health Company Press Release Johnson & Johnson Announces Kenvue as the Name for Planned New Consumer Health Company Press Release 1 Subsequent to the quarter. -- 4 of 24 -- FULL-YEAR 2022 GUIDANCE: Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP. ($ in Billions, except EPS) October 2022 July 2022 Adjusted Operational Sales1,2,5 Change vs. Prior Year 6.7% – 7.2% 6.5% – 7.5% Operational Sales2,5/ Mid-point2,5 Change vs. Prior Year / Mid-point $97.5B – $98.0B / $97.8B 6.7% – 7.2% / 7.0% $97.3B – $98.3B / $97.8B 6.5% – 7.5% / 7.0% Estimated Reported Sales3,5/ Mid-point3,5 Change vs. Prior Year / Mid-point $93.0B – $93.5B / $93.3B 1.8% – 2.3% / 2.1% $93.3B – $94.3B / $93.8B 2.1% – 3.1% / 2.6% Adjusted Operational EPS (Diluted)2,4/ Mid-point2,4 Change vs. Prior Year / Mid-point $10.70 – $10.75 / $10.73 9.2% – 9.7% / 9.5% $10.65 – $10.75 / $10.70 8.7% – 9.7% / 9.2% Adjusted EPS (Diluted)3,4 / Mid-point3,4 Change vs. Prior Year / Mid-point $10.02 – $10.07 / $10.05 2.3% – 2.8% / 2.6% $10.00 – $10.10 / $10.05 2.1% – 3.1% / 2.6 % 1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures 2 Non-GAAP financial measure; excludes the impact of translational currency 3 Calculated using Euro Average Rate: October 2022 = $1.04 and July 2022 = $1.05 (Illustrative purposes only) 4 Non-GAAP financial measure; excludes intangible amortization expense and special items 5 Excludes COVID-19 Vaccine Note: percentages may have been rounded Other modeling considerations will be provided on the webcast. WEBCAST INFORMATION: Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investors section of the company's website at events-and-presentations. -- 5 of 24 -- ABOUT JOHNSON & JOHNSON: At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. NON-GAAP FINANCIAL MEASURES: * “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investors section of the company's website at quarterly results. Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investors section of the company's website at quarterly results. NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS: This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy, and the anticipated separation of the Company’s Consumer Health business. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by -- 6 of 24 -- competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; the Company’s ability to satisfy the necessary conditions to consummate the separation of the Company’s Consumer Health business on a timely basis or at all; the Company’s ability to successfully separate the Company’s Consumer Health business and realize the anticipated benefits from the separation; the New Consumer Health Company’s ability to succeed as a standalone publicly traded company; and risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the company’s ability to execute business continuity plans, as a result of the COVID-19 pandemic. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Press Contacts: Investor Contacts: Jake Sargent Jessica Moore Sarah Wood (732) 524-1090 (732) 524-2955 (732) 524-2617 -- 7 of 24 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) Percent Change 2022 2021 Total Operations Currency 2022 2021 Total Operations Currency Sales to customers by segment of business Consumer Health (1) U.S. 1,659 $ 1,625 2.1 % 2.1 - 4,903 $ 4,987 (1.7) % (1.7) - International 2,136 2,187 (2.3) 6.7 (9.0) 6,283 6,320 (0.6) 6.0 (6.6) 3,795 3,812 (0.4) 4.7 (5.1) 11,186 11,307 (1.1) 2.6 (3.7) Pharmaceutical (1) U.S. 7,438 7,221 3.0 3.0 - 21,229 20,536 3.4 3.4 - International 5,776 5,661 2.0 16.7 (14.7) 18,171 16,927 7.3 18.5 (11.2) 13,214 12,882 2.6 9.0 (6.4) 39,400 37,463 5.2 10.2 (5.0) Pharmaceutical excluding COVID-19 Vaccine (1,3) U.S. 7,438 6,951 7.0 7.0 - 21,109 20,115 4.9 4.9 - International 5,287 5,429 (2.6) 11.3 (13.9) 16,801 16,582 1.3 11.7 (10.4) 12,725 12,380 2.8 8.9 (6.1) 37,910 36,697 3.3 8.0 (4.7) MedTech (2) U.S. 3,356 3,117 7.7 7.7 - 9,932 9,470 4.9 4.9 - International 3,426 3,527 (2.9) 8.5 (11.4) 10,719 10,731 (0.1) 8.2 (8.3) 6,782 6,644 2.1 8.1 (6.0) 20,651 20,201 2.2 6.6 (4.4) U.S. 12,453 11,963 4.1 4.1 - 36,064 34,993 3.1 3.1 - International 11,338 11,375 (0.3) 12.3 (12.6) 35,173 33,978 3.5 12.9 (9.4) Worldwide 23,791 23,338 1.9 8.1 (6.2) 71,237 68,971 3.3 7.9 (4.6) U.S. 12,453 11,693 6.5 6.5 - 35,944 34,572 4.0 4.0 - International 10,849 11,143 (2.6) 9.5 (12.1) 33,803 33,633 0.5 9.5 (9.0) Worldwide excluding COVID-19 Vaccine (3) 23,302 $ 22,836 2.0 % 8.0 (6.0) 69,747 $ 68,205 2.3 % 6.7 (4.4) Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. (1) Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes. (3) Refer to supplemental sales reconciliation schedule THIRD QUARTER NINE MONTHS Percent Change (2) Previously referred to as Medical Devices -- 8 of 24 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) Percent Change 2022 2021 Total Operations Currency 2022 2021 Total Operations Currency Sales to customers by geographic area U.S. 12,453 $ 11,963 4.1 % 4.1 - 36,064 $ 34,993 3.1 % 3.1 - Europe 5,524 5,587 (1.1) 14.5 (15.6) 17,633 16,669 5.8 18.2 (12.4) Western Hemisphere excluding U.S. 1,562 1,500 4.1 9.1 (5.0) 4,580 4,291 6.7 9.6 (2.9) Asia-Pacific, Africa 4,252 4,288 (0.9) 10.5 (11.4) 12,960 13,018 (0.4) 7.2 (7.6) International 11,338 11,375 (0.3) 12.3 (12.6) 35,173 33,978 3.5 12.9 (9.4) Worldwide 23,791 $ 23,338 1.9 % 8.1 (6.2) 71,237 $ 68,971 3.3 % 7.9 (4.6) Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. THIRD QUARTER NINE MONTHS Percent Change -- 9 of 24 -- Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers 23,791 $ 100.0 23,338 $ 100.0 1.9 Cost of products sold 7,807 32.8 7,250 31.1 7.7 Gross Profit 15,984 67.2 16,088 68.9 (0.6) Selling, marketing and administrative expenses 6,089 25.6 6,000 25.7 1.5 Research and development expense 3,597 15.1 3,422 14.7 5.1 In-process research and development - - 900 3.9 Interest (income) expense, net (99) (0.4) 7 0.0 Other (income) expense, net 493 2.1 1,850 7.9 Restructuring 82 0.3 60 0.2 Earnings before provision for taxes on income 5,822 24.5 3,849 16.5 51.3 Provision for taxes on income 1,364 5.8 182 0.8 649.5 Net earnings 4,458 $ 18.7 3,667 $ 15.7 21.6 Net earnings per share (Diluted) 1.68 $ 1.37 $ 22.6 Average shares outstanding (Diluted) 2,661.3 2,674.9 Effective tax rate 23.4 % 4.7 % Adjusted earnings before provision for taxes and net earnings (1) Earnings before provision for taxes on income 8,073 $ 33.9 8,058 $ 34.5 0.2 Net earnings 6,779 $ 28.5 6,968 $ 29.9 (2.7) Net earnings per share (Diluted) 2.55 $ 2.60 $ (1.9) Effective tax rate 16.0 % 13.5 % (1) See Reconciliation of Non-GAAP Financial Measures. THIRD QUARTER 2022 2021 -- 10 of 24 -- Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers 71,237 $ 100.0 68,971 $ 100.0 3.3 Cost of products sold 23,324 32.7 21,900 31.8 6.5 Gross Profit 47,913 67.3 47,071 68.2 1.8 Selling, marketing and administrative expenses 18,253 25.7 17,505 25.4 4.3 Research and development expense 10,762 15.1 9,994 14.5 7.7 In-process research and development 610 0.9 900 1.3 Interest (income) expense, net (137) (0.2) 83 0.1 Other (income) expense, net 664 0.9 480 0.7 Restructuring 237 0.3 169 0.2 Earnings before provision for taxes on income 17,524 24.6 17,940 26.0 (2.3) Provision for taxes on income 3,103 4.4 1,798 2.6 72.6 Net earnings 14,421 $ 20.2 16,142 $ 23.4 (10.7) Net earnings per share (Diluted) 5.41 $ 6.04 $ (10.4) Average shares outstanding (Diluted) 2,667.5 2,674.6 Effective tax rate 17.7 % 10.0 % Adjusted earnings before provision for taxes and net earnings (1) Earnings before provision for taxes on income 24,462 $ 34.3 24,125 $ 35.0 1.4 Net earnings 20,820 $ 29.2 20,517 $ 29.7 1.5 Net earnings per share (Diluted) 7.81 $ 7.67 $ 1.8 Effective tax rate 14.9 % 15.0 % (1) See Reconciliation of Non-GAAP Financial Measures. NINE MONTHS 2022 2021 -- 11 of 24 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures (Dollars in Millions Except Per Share Data) 2022 2021 2022 2021 Net Earnings, after tax- as reported $4,458 $3,667 $14,421 $16,142 Pre-tax Adjustments Intangible Asset Amortization expense 1,041 1,159 3,244 3,576 Litigation related 219 2,077 604 2,054 IPR&D - 900 610 900 Restructuring related 123 121 323 333 Acquisition, integration and divestiture related ¹ - 20 - (504) (Gains)/losses on securities 164 (127) 684 (335) Medical Device Regulation 2 78 59 208 161 COVID-19 Vaccine related costs 3 377 - 653 - Consumer Health separation costs 249 - 619 - Other - - (7) - Tax Adjustments Tax impact on special item adjustments 4 (379) (849) (1,085) (1,097) Consumer Health separation tax related costs 361 - 459 - Tax legislation and other tax related 88 (59) 87 (713) Adjusted Net Earnings, after tax $6,779 $6,968 $20,820 $20,517 Average shares outstanding (Diluted) 2,661.3 2,674.9 2,667.5 2,674.6 Adjusted net earnings per share (Diluted) $2.55 $2.60 $7.81 $7.67 Operational adjusted net earnings per share (Diluted) $2.75 $8.25 Notes: 1 2 3 4 Third Quarter Nine Months Ended Acquisition, integration and divestiture related for the nine months of 2021 primarily includes the gain on the divestiture of two Pharmaceutical brands outside of the U.S. European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance which is expected to be completed during 2024. The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's modification of its COVID-19 vaccine research program and manufacturing capacity to levels that meet all customer contractual requirements. -- 12 of 24 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Consumer Health Pharmaceutical MedTech Total WW As Reported (0.4)% 2.6% 2.1% 1.9% U.S. 2.1% 3.0% 7.7% 4.1% International (2.3)% 2.0% (2.9)% (0.3)% WW Currency (5.1) (6.4) (6.0) (6.2) U.S. - - - - International (9.0) (14.7) (11.4) (12.6) WW Operational 4.7% 9.0% 8.1% 8.1% U.S. 2.1% 3.0% 7.7% 4.1% International 6.7% 16.7% 8.5% 12.3% All Other Acquisitions and Divestitures 0.1 0.2 0.0 0.1 U.S. 0.2 0.2 (0.2) 0.1 International 0.0 0.1 0.2 0.1 WW Adjusted Operational 4.8% 9.2% 8.1% 8.2% U.S. 2.3% 3.2% 7.5% 4.2% International 6.7% 16.8% 8.7% 12.4% Adjusted Operational Sales Growth THIRD QUARTER 2022 ACTUAL vs. 2021 ACTUAL Segments Note: Percentages are based on actual, non-rounded figures and may not sum. -- 13 of 24 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Consumer Health Pharmaceutical MedTech Total WW As Reported (1.1)% 5.2% 2.2% 3.3% U.S. (1.7)% 3.4% 4.9% 3.1% International (0.6)% 7.3% (0.1)% 3.5% WW Currency (3.7) (5.0) (4.4) (4.6) U.S. - - - - International (6.6) (11.2) (8.3) (9.4) WW Operational 2.6% 10.2% 6.6% 7.9% U.S. (1.7)% 3.4% 4.9% 3.1% International 6.0% 18.5% 8.2% 12.9% All Other Acquisitions and Divestitures 0.5 0.1 0.1 0.2 U.S. 0.2 0.1 (0.2) 0.1 International 0.7 0.1 0.2 0.2 WW Adjusted Operational 3.1% 10.3% 6.7% 8.1% U.S. (1.5)% 3.5% 4.7% 3.2% International 6.7% 18.6% 8.4% 13.1% Note: Percentages are based on actual, non-rounded figures and may not sum. Adjusted Operational Sales Growth NINE MONTHS 2022 ACTUAL vs. 2021 ACTUAL Segments -- 14 of 24 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER NINE MONTHS 2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency CONSUMER HEALTH SEGMENT (2,3) OTC US 695 $ 686 1.4% 1.4% - 2,028 $ 1,960 3.5% 3.5% - Intl 825 798 3.4% 12.2% -8.8% 2,434 2,223 9.5% 16.3% -6.8% WW 1,519 1,484 2.5% 7.2% -4.7% 4,462 4,183 6.7% 10.3% -3.6% SKIN HEALTH / BEAUTY US 591 569 3.7% 3.7% - 1,764 1,862 -5.3% -5.3% - Intl 535 555 -3.6% 6.2% -9.8% 1,500 1,595 -6.0% 1.5% -7.5% WW 1,126 1,124 0.1% 5.0% -4.9% 3,264 3,457 -5.6% -2.2% -3.4% ORAL CARE US 158 150 5.2% 5.2% - 471 478 -1.5% -1.5% - Intl 217 248 -12.4% -4.3% -8.1% 664 762 -12.8% -7.2% -5.6% WW 375 398 -5.8% -0.7% -5.1% 1,135 1,240 -8.5% -5.0% -3.5% BABY CARE US 91 95 -4.0% -4.0% - 264 288 -8.2% -8.2% - Intl 283 296 -4.5% 3.4% -7.9% 840 879 -4.4% 0.8% -5.2% WW 375 391 -4.3% 1.6% -5.9% 1,105 1,167 -5.4% -1.5% -3.9% WOMEN'S HEALTH US 2 3 -22.0% -22.0% - 9 9 -2.8% -2.8% - Intl 222 229 -2.7% 8.4% -11.1% 674 675 -0.1% 8.0% -8.1% WW 225 232 -3.0% 7.9% -10.9% 684 684 -0.1% 7.8% -7.9% WOUND CARE / OTHER US 122 122 -0.2% -0.2% - 366 390 -6.0% -6.0% - Intl 53 61 -11.4% -7.1% -4.3% 170 186 -8.2% -5.4% -2.8% WW 176 182 -3.9% -2.5% -1.4% 537 575 -6.7% -5.8% -0.9% TOTAL CONSUMER HEALTH US 1,659 1,625 2.1% 2.1% - 4,903 4,987 -1.7% -1.7% - Intl 2,136 2,187 -2.3% 6.7% -9.0% 6,283 6,320 -0.6% 6.0% -6.6% WW 3,795 $ 3,812 -0.4% 4.7% -5.1% 11,186 $ 11,307 -1.1% 2.6% -3.7% See footnotes at end of schedule % Change % Change -- 15 of 24 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER NINE MONTHS PHARMACEUTICAL SEGMENT (2,3) 2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency IMMUNOLOGY US 2,876 $ 2,771 3.8% 3.8% - 8,230 $ 7,932 3.8% 3.8% - Intl 1,411 1,480 -4.7% 8.9% -13.6% 4,587 4,464 2.8% 12.9% -10.1% WW 4,287 4,250 0.9% 5.6% -4.7% 12,817 12,395 3.4% 7.1% -3.7% REMICADE US 350 480 -27.0% -27.0% - 1,099 1,508 -27.1% -27.1% - US Exports (4) 39 47 -16.9% -16.9% - 163 197 -17.2% -17.2% - Intl 169 234 -27.8% -22.8% -5.0% 606 721 -16.0% -11.9% -4.1% WW 558 761 -26.6% -25.1% -1.5% 1,868 2,426 -23.0% -21.8% -1.2% SIMPONI / SIMPONI ARIA US 298 295 0.9% 0.9% - 886 840 5.4% 5.4% - Intl 248 276 -10.4% 3.0% -13.4% 797 877 -9.2% 0.4% -9.6% WW 545 571 -4.6% 1.9% -6.5% 1,682 1,717 -2.0% 2.9% -4.9% STELARA US 1,655 1,569 5.5% 5.5% - 4,766 4,396 8.4% 8.4% - Intl 794 809 -1.9% 12.9% -14.8% 2,571 2,404 6.9% 18.2% -11.3% WW 2,449 2,378 3.0% 8.0% -5.0% 7,336 6,800 7.9% 11.9% -4.0% TREMFYA US 530 376 40.7% 40.7% - 1,303 975 33.6% 33.6% - Intl 200 161 24.6% 44.5% -19.9% 613 459 33.7% 49.0% -15.3% WW 729 537 35.9% 41.9% -6.0% 1,916 1,434 33.6% 38.5% -4.9% OTHER IMMUNOLOGY US 5 3 * * - 14 15 -3.5% -3.5% - Intl 0 0 * * * 0 3 * * * WW 5 3 * * * 14 18 -19.3% -19.3% 0.0% INFECTIOUS DISEASES US 390 679 -42.7% -42.7% - 1,266 1,635 -22.6% -22.6% - Intl 905 698 29.7% 49.1% -19.4% 2,642 1,758 50.3% 67.1% -16.8% WW 1,295 1,378 -6.0% 3.8% -9.8% 3,908 3,394 15.2% 23.9% -8.7% COVID-19 VACCINE US 0 270 * * - 120 421 -71.5% -71.5% - Intl 489 233 * * * 1,370 346 * * * WW 489 502 -2.7% 13.1% -15.8% 1,490 766 * * * EDURANT / rilpivirine US 9 12 -27.1% -27.1% - 27 31 -14.5% -14.5% - Intl 237 247 -4.2% 9.8% -14.0% 691 733 -5.7% 4.8% -10.5% WW 245 259 -5.2% 8.2% -13.4% 718 764 -6.1% 4.0% -10.1% PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA US 372 380 -2.2% -2.2% - 1,096 1,128 -2.9% -2.9% - Intl 112 137 -17.9% -6.3% -11.6% 354 440 -19.5% -11.2% -8.3% WW 485 517 -6.4% -3.3% -3.1% 1,450 1,568 -7.5% -5.2% -2.3% OTHER INFECTIOUS DISEASES US 10 18 -46.4% -46.4% - 24 55 -57.2% -57.2% - Intl 68 82 -17.1% -10.8% -6.3% 228 240 -5.0% 0.2% -5.2% WW 77 99 -22.4% -17.2% -5.2% 251 295 -14.8% -10.6% -4.2% % Change % Change -- 16 of 24 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER NINE MONTHS 2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency NEUROSCIENCE US 919 835 10.0% 10.0% - 2,658 2,448 8.6% 8.6% - Intl 763 845 -9.9% 1.8% -11.7% 2,498 2,751 -9.2% -0.6% -8.6% WW 1,681 1,680 0.0% 5.9% -5.9% 5,156 5,199 -0.8% 3.7% -4.5% CONCERTA / Methylphenidate US 41 35 19.3% 19.3% - 114 117 -2.2% -2.2% - Intl 117 122 -4.4% 8.0% -12.4% 362 372 -2.6% 6.5% -9.1% WW 158 157 0.8% 10.5% -9.7% 476 489 -2.5% 4.4% -6.9% INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA US 684 648 5.3% 5.3% - 2,036 1,882 8.1% 8.1% - Intl 348 355 -2.3% 12.2% -14.5% 1,097 1,111 -1.3% 9.4% -10.7% WW 1,031 1,004 2.6% 7.8% -5.2% 3,132 2,994 4.6% 8.6% -4.0% RISPERDAL CONSTA US 67 71 -6.1% -6.1% - 195 210 -7.1% -7.1% - Intl 52 69 -24.2% -11.3% -12.9% 178 242 -26.3% -17.0% -9.3% WW 119 140 -14.9% -8.6% -6.3% 373 452 -17.4% -12.4% -5.0% OTHER NEUROSCIENCE US 127 81 57.2% 57.2% - 313 239 31.1% 31.1% - Intl 246 298 -17.9% -10.0% -7.9% 861 1,026 -16.2% -10.2% -6.0% WW 374 379 -1.9% 4.3% -6.2% 1,174 1,265 -7.3% -2.4% -4.9% ONCOLOGY US 1,812 1,525 18.8% 18.8% - 5,073 4,364 16.2% 16.2% - Intl 2,252 2,140 5.2% 20.9% -15.7% 6,983 6,406 9.0% 20.8% -11.8% WW 4,064 3,665 10.9% 20.0% -9.1% 12,056 10,770 11.9% 19.0% -7.1% DARZALEX US 1,097 841 30.3% 30.3% - 3,071 2,302 33.4% 33.4% - Intl 955 739 29.3% 48.2% -18.9% 2,823 2,076 36.0% 50.8% -14.8% WW 2,052 1,580 29.8% 38.7% -8.9% 5,894 4,378 34.6% 41.6% -7.0% ERLEADA US 254 214 19.1% 19.1% - 693 578 20.0% 20.0% - Intl 235 130 * * * 647 329 * * * WW 490 344 42.2% 51.2% -9.0% 1,340 907 47.7% 54.9% -7.2% IMBRUVICA US 353 413 -14.6% -14.6% - 1,072 1,311 -18.3% -18.3% - Intl 559 654 -14.6% -2.5% -12.1% 1,847 1,996 -7.5% 1.9% -9.4% WW 911 1,066 -14.6% -7.2% -7.4% 2,918 3,307 -11.8% -6.1% -5.7% ZYTIGA / abiraterone acetate US 16 25 -33.1% -33.1% - 54 96 -43.4% -43.4% - Intl 440 523 -15.9% -1.2% -14.7% 1,446 1,653 -12.5% -1.9% -10.6% WW 456 548 -16.7% -2.6% -14.1% 1,500 1,749 -14.2% -4.2% -10.0% OTHER ONCOLOGY US 92 32 * * - 183 76 * * - Intl 64 94 -32.1% -22.6% -9.5% 220 352 -37.5% -31.2% -6.3% WW 155 126 23.1% 30.2% -7.1% 403 428 -5.9% -0.8% -5.1% % Change % Change -- 17 of 24 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER NINE MONTHS 2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency PULMONARY HYPERTENSION US 604 610 -1.1% -1.1% - 1,736 1,778 -2.4% -2.4% - Intl 247 258 -3.8% 12.5% -16.3% 810 821 -1.3% 10.5% -11.8% WW 852 868 -1.9% 3.0% -4.9% 2,547 2,599 -2.0% 1.7% -3.7% OPSUMIT US 289 299 -3.4% -3.4% - 827 861 -4.0% -4.0% - Intl 152 159 -4.7% 11.6% -16.3% 495 510 -3.0% 8.7% -11.7% WW 441 458 -3.9% 1.8% -5.7% 1,322 1,371 -3.6% 0.7% -4.3% UPTRAVI US 283 265 6.6% 6.6% - 824 792 3.9% 3.9% - Intl 50 44 14.2% 29.5% -15.3% 162 135 20.4% 32.1% -11.7% WW 333 309 7.7% 9.9% -2.2% 986 927 6.3% 8.0% -1.7% OTHER PULMONARY HYPERTENSION US 33 47 -29.5% -29.5% - 86 125 -31.3% -31.3% - Intl 46 54 -15.7% 1.2% -16.9% 154 176 -13.0% -1.0% -12.0% WW 78 101 -22.1% -12.9% -9.2% 239 301 -20.5% -13.5% -7.0% CARDIOVASCULAR / METABOLISM / OTHER US 837 800 4.5% 4.5% - 2,266 2,379 -4.8% -4.8% - Intl 198 241 -17.5% -8.8% -8.7% 651 727 -10.4% -3.8% -6.6% WW 1,034 1,041 -0.6% 1.4% -2.0% 2,916 3,106 -6.1% -4.5% -1.6% XARELTO US 689 636 8.4% 8.4% - 1,806 1,794 0.7% 0.7% - Intl - - - - - - - - - - WW 689 636 8.4% 8.4% - 1,806 1,794 0.7% 0.7% - INVOKANA / INVOKAMET US 49 66 -25.8% -25.8% - 164 249 -34.1% -34.1% - Intl 60 67 -11.0% -2.5% -8.5% 193 194 -0.6% 6.1% -6.7% WW 109 133 -18.4% -14.1% -4.3% 357 443 -19.5% -16.6% -2.9% OTHER US 98 98 -0.1% -0.1% - 295 336 -12.2% -12.2% - Intl 138 173 -20.0% -11.3% -8.7% 458 533 -14.0% -7.3% -6.7% WW 236 271 -12.8% -7.3% -5.5% 753 869 -13.3% -9.2% -4.1% TOTAL PHARMACEUTICAL US 7,438 7,221 3.0% 3.0% - 21,229 20,536 3.4% 3.4% - Intl 5,776 5,661 2.0% 16.7% -14.7% 18,171 16,927 7.3% 18.5% -11.2% WW 13,214 $ 12,882 2.6% 9.0% -6.4% 39,400 $ 37,463 5.2% 10.2% -5.0% See footnotes at end of schedule % Change % Change -- 18 of 24 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER NINE MONTHS MEDTECH SEGMENT (2,3,5) 2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency INTERVENTIONAL SOLUTIONS US 547 $ 444 23.2% 23.2% - 1,566 $ 1,353 15.7% 15.7% - Intl 513 513 0.0% 13.0% -13.0% 1,636 1,599 2.3% 11.1% -8.8% WW 1,060 957 10.8% 17.7% -6.9% 3,202 2,952 8.5% 13.2% -4.7% ORTHOPAEDICS US 1,309 1,249 4.8% 4.8% - 3,936 3,821 3.0% 3.0% - Intl 785 843 -6.9% 4.6% -11.5% 2,504 2,611 -4.1% 4.3% -8.4% WW 2,095 2,093 0.1% 4.7% -4.6% 6,440 6,433 0.1% 3.5% -3.4% HIPS US 228 209 9.1% 9.1% - 693 651 6.5% 6.5% - Intl 124 146 -15.1% -4.5% -10.6% 437 451 -3.3% 4.6% -7.9% WW 352 355 -0.9% 3.5% -4.4% 1,129 1,102 2.5% 5.7% -3.2% KNEES US 203 184 9.8% 9.8% - 620 579 6.9% 6.9% - Intl 115 131 -12.8% -2.1% -10.7% 386 403 -4.4% 3.7% -8.1% WW 317 316 0.4% 4.9% -4.5% 1,005 983 2.3% 5.6% -3.3% TRAUMA US 473 455 3.8% 3.8% - 1,412 1,352 4.4% 4.4% - Intl 244 260 -6.0% 6.5% -12.5% 749 805 -7.0% 2.3% -9.3% WW 717 715 0.2% 4.8% -4.6% 2,161 2,157 0.2% 3.6% -3.4% SPINE, SPORTS & OTHER US 406 401 1.3% 1.3% - 1,211 1,239 -2.2% -2.2% - Intl 303 306 -1.1% 10.2% -11.3% 933 952 -2.0% 6.1% -8.1% WW 708 706 0.3% 5.2% -4.9% 2,144 2,190 -2.1% 1.4% -3.5% % Change % Change -- 19 of 24 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER NINE MONTHS 2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency SURGERY US 984 948 3.7% 3.7% - 2,897 2,881 0.5% 0.5% - Intl 1,439 1,457 -1.2% 9.3% -10.5% 4,410 4,418 -0.2% 7.3% -7.5% WW 2,422 2,405 0.7% 7.1% -6.4% 7,306 7,299 0.1% 4.6% -4.5% ADVANCED US 457 440 3.8% 3.8% - 1,328 1,304 1.8% 1.8% - Intl 701 705 -0.4% 9.8% -10.2% 2,132 2,126 0.3% 7.2% -6.9% WW 1,158 1,144 1.2% 7.5% -6.3% 3,460 3,430 0.9% 5.2% -4.3% GENERAL US 527 508 3.6% 3.6% - 1,569 1,577 -0.5% -0.5% - Intl 737 752 -2.0% 8.8% -10.8% 2,277 2,292 -0.6% 7.3% -7.9% WW 1,264 1,261 0.3% 6.7% -6.4% 3,846 3,869 -0.6% 4.1% -4.7% VISION US 517 475 8.8% 8.8% - 1,534 1,414 8.5% 8.5% - Intl 689 714 -3.5% 8.4% -11.9% 2,170 2,103 3.2% 12.9% -9.7% WW 1,206 1,189 1.4% 8.6% -7.2% 3,704 3,517 5.3% 11.1% -5.8% CONTACT LENSES / OTHER US 405 359 12.6% 12.6% - 1,179 1,082 9.0% 9.0% - Intl 503 522 -3.6% 9.5% -13.1% 1,533 1,525 0.5% 11.1% -10.6% WW 908 882 3.0% 10.8% -7.8% 2,712 2,607 4.0% 10.2% -6.2% SURGICAL US 112 117 -3.2% -3.2% - 355 333 6.8% 6.8% - Intl 186 191 -3.3% 5.6% -8.9% 637 577 10.3% 17.6% -7.3% WW 298 308 -3.2% 2.3% -5.5% 992 910 9.0% 13.6% -4.6% TOTAL MEDTECH US 3,356 3,117 7.7% 7.7% - 9,932 9,470 4.9% 4.9% - Intl 3,426 3,527 -2.9% 8.5% -11.4% 10,719 10,731 -0.1% 8.2% -8.3% WW 6,782 $ 6,644 2.1% 8.1% -6.0% 20,651 $ 20,201 2.2% 6.6% -4.4% Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. * Percentage greater than 100% or not meaningful (1) Operational growth excludes the effect of translational currency (2) Unaudited (3) Certain prior year amounts have been reclassified to conform to current year product disclosures (4) Reported as U.S. sales (5) Previously referred to as Medical Devices % Change % Change -- 20 of 24 -- 2022 2021 Total Operations Currency 2022 2021 Total Operations Currency Pharmaceutical U.S. 7,438 $ 7,221 3.0 % 3.0 - 21,229 $ 20,536 3.4 % 3.4 - International 5,776 5,661 2.0 16.7 (14.7) 18,171 16,927 7.3 18.5 (11.2) Worldwide 13,214 12,882 2.6 9.0 (6.4) 39,400 37,463 5.2 10.2 (5.0) COVID-19 Vaccine U.S. 0 270 * * - 120 421 (71.5) (71.5) - International 489 233 * * * 1,370 346 * * * Worldwide 489 502 (2.7) 13.1 (15.8) 1,490 766 * * * Pharmaceutical excluding COVID-19 Vaccine U.S. 7,438 6,951 7.0 7.0 - 21,109 20,115 4.9 4.9 - International 5,287 5,429 (2.6) 11.3 (13.9) 16,801 16,582 1.3 11.7 (10.4) Worldwide 12,725 12,380 2.8 8.9 (6.1) 37,910 36,697 3.3 8.0 (4.7) Worldwide U.S. 12,453 11,963 4.1 4.1 - 36,064 34,993 3.1 3.1 - International 11,338 11,375 (0.3) 12.3 (12.6) 35,173 33,978 3.5 12.9 (9.4) Worldwide 23,791 23,338 1.9 8.1 (6.2) 71,237 68,971 3.3 7.9 (4.6) COVID-19 Vaccine U.S. 0 270 * * - 120 421 (71.5) (71.5) - International 489 233 * * * 1,370 346 * * * Worldwide 489 502 (2.7) 13.1 (15.8) 1,490 766 * * * Worldwide U.S. 12,453 11,693 6.5 6.5 - 35,944 34,572 4.0 4.0 - International 10,849 11,143 (2.6) 9.5 (12.1) 33,803 33,633 0.5 9.5 (9.0) Worldwide excluding COVID-19 Vaccine 23,302 $ 22,836 2.0 % 8.0 (6.0) 69,747 $ 68,205 2.3 % 6.7 (4.4) Note: Columns and rows within tables may not add due to rounding * Percentage greater than 100% or not meaningful Supplemental Sales Reconciliation (Unaudited) (Dollars in Millions) THIRD QUARTER NINE MONTHS Percent Change Percent Change -- 21 of 24 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures 2022 2021 2022 2021 2022 2021 2022 2021 2022 2021 2022 2021 Reported Income Before Tax by Segment $ 809 (577) 4,249 4,200 1,124 423 (111) (197) (249) - 5,822 3,849 % to Sales 21.3% -15.1% 32.2% 32.6% 16.6% 6.4% -0.5% -0.8% -1.0% 0.0% 24.5% 16.5% Intangible asset amortization expense 83 103 698 799 260 257 - - - - 1,041 1,159 In-process research and development - - - 900 - - - - - 900 Litigation related - 1,359 7 756 212 (38) - - - - 219 2,077 Loss/(gain) on securities - 1 177 (135) (13) 7 - - - - 164 (127) Restructuring related 31 36 23 17 69 68 - - - - 123 121 Acquisition, integration and divestiture related - - - 3 - 17 - - - - - 20 Medical Device Regulation - - - - 78 59 - - - - 78 59 COVID-19 Vaccine related costs - - 377 - - - - - - - 377 - Consumer Health separation costs - - - - - - - - 249 - 249 - Other - - - - - - - - - - - - Adjusted Income Before Tax by Segment $ 923 922 5,531 5,640 1,730 1,693 (111) (197) - - 8,073 8,058 % to Sales 24.3% 24.2% 41.9% 43.8% 25.5% 25.5% -0.5% -0.8% 0.0% 0.0% 33.9% 34.5% 1 Prior year income before tax has been reclassified as Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes *Estimated as of 10/18/2022 Q3 QTD - Income Before Tax by Segment* Dollars in Millions Consumer Health Separation Costs Consumer Health1 Pharmaceutical1 MedTech Unallocated Worldwide Total -- 22 of 24 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures 2022 2021 2022 2021 2022 2021 2022 2021 2022 2021 2022 2021 Reported Income Before Tax by Segment $ 2,279 1,131 12,593 13,663 3,742 3,798 (471) (652) (619) - 17,524 17,940 % to Sales 20.4% 10.0% 32.0% 36.5% 18.1% 18.8% -0.7% -0.9% -0.9% 0.0% 24.6% 26.0% Intangible asset amortization expense 277 314 2,194 2,497 773 765 - - - - 3,244 3,576 In-process research and development - - 610 - - 900 - - - - 610 900 Litigation related 78 1,481 43 675 483 (102) - - - - 604 2,054 Loss/(gain) on securities - (19) 673 (249) 11 (67) - - - - 684 (335) Restructuring related 70 91 32 54 221 188 - - - - 323 333 Acquisition, integration and divestiture related - - - (567) - 63 - - - - - (504) Medical Device Regulation - - - - 208 161 - - - - 208 161 COVID-19 Vaccine related costs - - 653 - - - - - - - 653 - Consumer Health separation costs - - - - - - - - 619 - 619 - Other - - - - - - (7) - - - (7) - Adjusted Income Before Tax by Segment $ 2,704 2,998 16,798 16,073 5,438 5,706 (478) (652) - - 24,462 24,125 % to Sales 24.2% 26.5% 42.6% 42.9% 26.3% 28.2% -0.7% -0.9% 0.0% 0.0% 34.3% 35.0% 1 Prior year income before tax has been reclassified as Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes *Estimated as of 10/18/2022 Q3 YTD - Income Before Tax by Segment* Dollars in Millions Consumer Health Separation Costs Consumer Health1 Pharmaceutical1 MedTech Unallocated Worldwide Total -- 23 of 24 -- Third Quarter Third Quarter Oct 2, 2022 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Other Oct 2, 2022 Non-GAAP Cost of products sold 7,807 $ (1,041) (13) (29) (102) - - - - 6,622 Selling, marketing and admin expenses 6,089 (7) (2) 6,080 Research and development expense 3,597 - (42) (80) - 3,475 Other (Income) / Expense 493 - (219) (28) - (164) (195) (247) - - (360) In-process research and development - - - Restructuring 82 (82) - Provision for taxes on income 1,364 164 (7) - 23 - 43 15 96 45 (361) (88) - 1,294 Net Earnings 4,458 877 226 - 100 - 121 63 281 204 361 88 - 6,779 Third Quarter Third Quarter Oct 3, 2021 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Other Oct 3, 2021 Non-GAAP Cost of products sold 7,250 $ (1,133) (18) (22) 6,077 Selling, marketing and admin expenses 6,000 (6) 5,994 Research and development expense 3,422 - (31) 3,391 Other (Income) / Expense 1,850 (26) (2,077) (43) (20) 127 - - - - (189) In-process research and development 900 (900) - Restructuring 60 (60) - Provision for taxes on income 182 165 433 202 22 (6) 22 11 - - - 59 - 1,090 Net Earnings 3,667 994 1,644 698 99 26 (149) 48 - - - (59) - 6,968 Nine Months Nine Months Oct 2, 2022 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Other Oct 2, 2022 Non-GAAP Cost of products sold 23,324 $ (3,232) (46) (76) (296) 19,674 Selling, marketing and admin expenses 18,253 (19) (2) 18,232 Research and development expense 10,762 - (113) (190) 10,459 Other (Income) / Expense 664 (12) (604) (40) - (684) (167) (617) - 7 (1,453) In-process research and development 610 (610) - Restructuring 237 (237) - Provision for taxes on income 3,103 502 (89) 138 60 - 164 39 161 112 (459) (87) (2) 3,642 Net Earnings 14,421 2,742 693 472 263 - 520 169 492 507 459 87 (5) 20,820 Nine Months Nine Months Oct 3, 2021 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Other Oct 3, 2021 Non-GAAP Cost of products sold 21,900 $ (3,550) (65) (59) 18,226 Selling, marketing and admin expenses 17,505 (17) 17,488 Research and development expense 9,994 - (85) 9,909 Other (Income) / Expense 480 (26) (2,054) (99) 504 335 - - - - (860) In-process research and development 900 (900) - Restructuring 169 (169) - Provision for taxes on income 1,798 505 432 202 59 (104) (27) 30 - - - 713 - 3,608 Net Earnings 16,142 3,071 1,622 698 274 (400) (308) 131 - - - (713) - 20,517 (1) 2021 primarily includes gains on the divestitures of two Pharmaceutical brands outside of the United States. Tax legislation and other tax related Consumer Health separation tax related costs In-process research and development Acquisition, integration and divestiture related (1) (Loss)/gain on securities COVID-19 Vaccine Related Costs Consumer Health separation costs Tax legislation and other tax related Year to Date Consumer Health separation tax related costs In-process research and development Acquisition, integration and divestiture related (Loss)/gain on securities COVID-19 Vaccine Related Costs Consumer Health separation costs Tax legislation and other tax related Consumer Health separation tax related costs In-process research and development Acquisition, integration and divestiture related (Loss)/gain on securities COVID-19 Vaccine Related Costs Consumer Health separation costs Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Quarter to Date Consumer Health separation tax related costs In-process research and development Acquisition, integration and divestiture related (Loss)/gain on securities COVID-19 Vaccine Related Costs Consumer Health separation costs Tax legislation and other tax related -- 24 of 24 --